Skip to main content

Table 2 Demographics and clinical parameters of the patients studied for plasma antibodies against oxidized lipid epitopes

From: Lipid accumulation, lipid oxidation, and low plasma levels of acquired antibodies against oxidized lipids associate with degeneration and rupture of the intracranial aneurysm wall

Variables Bleeding status P-value
  No SAH Prior SAH  
(n = 41) (n = 84)
A. Patients    
Age (years) 54y. (28–70) 55.5y. (11–84) 0.298
Gender (females) 71% (30/42) 71% (60/84) 1.00
Patients with multiple sIAs (≥2) 36% (15/42) 46% (39/84) 0.340
Patients with more than one known aneurysmal SAH - 4% (3/84) NA
Severity of the SAH (Hunt&Hess-grading)    NA
   0 (no bleeding) 42 -  
   1 (asymptomatic or mild headache / nuchal rigidity) - 7% (6/84)  
   2 (moderate headache / nuchal rigidity) - 31% (26/84)  
   3 (drowsiness/confusion, mild neurological deficit) - 27% (23/84)  
   4 (stupor, moderate-severe hemiparesis) - 18% (15/84)  
   5 (coma or decerebrate posturing) - 8% (7/84)  
   Hunt & Hess for the prior bleeding not known   7% (6/84)  
Known familial background 29% (12/42) 7% (6/84) <0.001*
Smoking    <0.001 #
   Current 50% (21/42) 42% (35/84)  
   Ex-smoker 14% (6/42) 4% (3/84)  
   Never smoked 36% (15/42) 21% (18/84)  
   Status not known 0 32% (27/84)  
Hypertension 36% (15/42) 40% (34/84) 0.799
  1. Median and range are given for continuous variables, proportions for categorical variables. Mann–Whitney U-test was used for continous and Fisher’s Exact test for categorical variables. NA, Not applicable.
  2. * The percentage of unknown family histories is very high, especially in the PRIOR SAH group (76%, 64/84) making conclusions of the familial background unreliable.
  3. #Although the difference of smoking habits between patients with unruptured sIAs and a history of aneurysmal SAH was highly significant, it is important to notice that in the SAH group the smoking history of 32% of patients was not unknown, which may significantly affect the result.